CD38 as immunomodulator in cancer

被引:19
作者
Li, Yanli [1 ]
Yang, Rui [1 ]
Chen, Limo [2 ]
Wu, Sufang [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Shanghai, Peoples R China
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
关键词
biomarker; cancer immunotherapy; CD38; immune checkpoint therapy; immunomodulation; tumor microenvironment; ANTIBODIES TARGETING CD38; MONOCLONAL-ANTIBODIES; BONE-MARROW; ADP-RIBOSE; ANTI-CD38; AUTOANTIBODIES; MULTIPLE-MYELOMA; DENDRITIC CELLS; LUNG-CANCER; EXPRESSION; DARATUMUMAB;
D O I
10.2217/fon-2020-0401
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CD38 is a transmembrane glycoprotein that is widely expressed in a variety of human tissues and cells, especially those in the immune system. CD38 protein was previously considered as a cell activation marker, and today monoclonal antibodies targeting CD38 have witnessed great achievements in multiple myeloma and promoted researchers to conduct research on other tumors. In this review, we provide a wide-ranging review of the biology and function of the human molecule outside the field of myeloma. We focus mainly on current research findings to summarize and update the findings gathered from diverse areas of study. Based on these findings, we attempt to extend the role of CD38 in the context of therapy of solid tumors and expand the role of the molecule from a simple marker to an immunomodulator.
引用
收藏
页码:2853 / 2861
页数:9
相关论文
共 50 条
  • [11] CD38 as theranostic target in oncology
    Valentina, Bocuzzi
    Jessica, Bridoux
    Michelle, Pirotte
    Nadia, Withofs
    Roland, Hustinx
    Matthias, D'Huyvetter
    Jo, Caers
    Guillaume, Marcion
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [12] The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging
    Chini, Eduardo N.
    Chini, Claudia C. S.
    Netto, Jair Machado Espindola
    de Oliveira, Guilherme C.
    van Schooten, Wim
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2018, 39 (04) : 424 - 436
  • [13] Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38
    Li, Song
    Chen, Dianze
    Yang, Yanan
    Guo, Huiqin
    Liu, Dandan
    Sun, Nana
    Bai, Xing
    Wang, Kaili
    Li, Tengfei
    Li, Guanghui
    Yang, Chunmei
    Zhang, Wei
    Zhang, Li
    Zhao, Gui
    Peng, Liang
    Liu, Sijin
    Tu, Xiaoping
    Zhang, Ruliang
    Tian, Wenzhi
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [14] CD38 expression as response of hematopoietic system to cancer
    Albeniz, Isil
    Demir-Coskun, Ozlem
    Turker-Sener, Leyla
    Bas, Aycan
    Asoglu, Oktar
    Nurten, Rustem
    ONCOLOGY LETTERS, 2011, 2 (04) : 659 - 664
  • [15] IFN-γ and CD38 in Hyperprogressive Cancer Development
    Angelicola, Stefania
    Ruzzi, Francesca
    Landuzzi, Lorena
    Scalambra, Laura
    Gelsomino, Francesco
    Ardizzoni, Andrea
    Nanni, Patrizia
    Lollini, Pier-Luigi
    Palladini, Arianna
    CANCERS, 2021, 13 (02) : 1 - 25
  • [16] Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
    van de Donk, Niels W. C. J.
    Janmaat, Maarten L.
    Mutis, Tuna
    van Bueren, Jeroen J. Lammerts
    Ahmadi, Tahamtan
    Sasser, A. Kate
    Lokhorst, Henk M.
    Parren, Paul W. H. I.
    IMMUNOLOGICAL REVIEWS, 2016, 270 (01) : 95 - 112
  • [17] CD38 as an immunotherapeutic target in multiple myeloma
    Bonello, Francesca
    D'Agostino, Mattia
    Moscvin, Maria
    Cerrato, Chiara
    Boccadoro, Mario
    Gay, Francesca
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (12) : 1209 - 1221
  • [18] CD38 as a multifaceted immunotherapeutic target in CLL
    Paulus, Aneel
    Malavasi, Fabio
    Chanan-Khan, Asher
    LEUKEMIA & LYMPHOMA, 2022, 63 (10) : 2265 - 2275
  • [19] Immunotherapies targeting CD38 in Multiple Myeloma
    Atanackovic, Djordje
    Steinbach, Mary
    Radhakrishnan, Sabarinath Venniyil
    Luetkens, Tim
    ONCOIMMUNOLOGY, 2016, 5 (11):
  • [20] Daratumumab induces CD38 internalization and impairs myeloma cell adhesion
    Ghose, Jayeeta
    Viola, Domenico
    Terrazas, Cesar
    Caserta, Enrico
    Troadec, Estelle
    Khalife, Jihane
    Gunes, Emine Gulsen
    Sanchez, James
    McDonald, Tinisha
    Marcucci, Guido
    Kaur, Balveen
    Rosenzweig, Michael
    Keats, Jonathan
    Rosen, Steven
    Krishnan, Amrita
    Satoskar, Abhay R.
    Hofmeister, Craig C.
    Pichiorri, Flavia
    ONCOIMMUNOLOGY, 2018, 7 (10):